Business Wire

Verlingue Acquires the Insurance Broker Cabinet Depeyre, a Specialist in Complex Corporate Risks, and the Underwriting Agency Depeyre Solutions

Share

Verlingue, a subsidiary of the French Adelaïde Group, specialising in corporate protection, is continuing its external growth strategy with two new acquisitions that will consolidate its presence in the Grand Est region (France).

Set up in 1997, the insurance broker Cabinet Depeyre specialises in consulting and management of complex business risks. Depeyre Solutions, created in 2014, is an underwriting agency specialising in business risks for brokers and general agents. The group has 23 employees for just over €4m in commissions.

The insurance broker Cabinet Depeyre, specialised in complex business risks, works with its customers to analyse, prevent and manage their risks. The Cabinet Depeyre teams have acquired special expertise in high-pressure sectors such as the wood processing industry, transport and logistics, manufacturers and traders of building materials, etc., whether in matters of Civil Liability or Property Damage.

Depeyre Solutions, which is intended to remain an autonomous entity affiliated to the Adelaïde Group, sells insurance solutions as an underwriting agent (MGA) for business risks, mainly in the fields of Vehicle Fleet, Property Damage and Civil Liability.

“With Verlingue, I firmly believe that our teams will be able to provide even better support to our customers and provide them with all the solutions offered by a company with which we already share common values and a vision of our role as a trusted partner in risk management,” says Jean-Michel Depeyre, head of both companies.

After the acquisition of RT Global Insurance in Portugal at the end of 2022, the acquisition of Cabinet Depeyre and Depeyre Solutions in France consolidates Verlingue's external growth dynamic as part of its 2024 strategic plan.

Verlingue has a powerful, sustainable and profitable growth strategy in place. In a consolidating business sector, being a family-owned broker with an ambitious and long-term vision allows us to map out great plans for the teams that decide to join our adventure. I’m delighted that Jean-Michel Depeyre has jumped on board,” says Gilles Bénéplanc – CEO of the Adelaide Group and Verlingue.

About Verlingue

An insurance broker specializing in business protection, Verlingue is a subsidiary of the Adelaïde Group.

Working alongside entrepreneurs, Verlingue’s goal is to harness corporate risk management and employee protection to drive its clients’ value creation and performance.

With offices in France, Portugal, Great Britain and Switzerland, and through partners in over 100 countries, Verlingue works with its clients over the long term and at all times to better understand and plan ahead for new risks in order to develop simple yet effective solutions to protect their business (corporate risk) and staff (supplementary social protection schemes and pensions).

1,200 employees, 400 of whom are based outside France
€2.2bn in premiums negotiated on behalf of its clients
24 offices in Europe
LinkedIn / www.verlingue.fr

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contact:
Adelaïde Group - Thomas Barbelet – thomas.barbelet@verlingue.fr – +33(0)6 72 75 49 14
Epoka Agency – Lucie Fortin – lfortin@epoka.fr – +33(0)6 19 68 70 18

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit28.4.2024 14:57:00 EEST | Press release

TUM (Technical University of Munich) from Germany, claimed victory at the inaugural Abu Dhabi Autonomous Racing League (A2RL), at Yas Marina Circuit on Saturday (April 27). As the cars lined up on the grid, with antennae, sensors, AI capabilities, and drive-by-wire systems instead of human drivers, eight teams vied with one another over two days of races and challenges. TUM beat back the competition with its coding and engineering skills in a world-first, four-car race finale, to claim the winner’s share of US$2.25 million prize pot. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240428292385/en/ TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit - (Photo: AETOSWire) Bringing a science experiment to the racetrack, the inaugural race pushed the boundaries of autonomous technology while adding entertainment value to extreme sports at an unprecedented scale. A2RL drew over 10,000

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye